Cellectis: Monthly information on share capital and company voting rights
Cellectis, a clinical-stage biopharmaceutical company, is pioneering allogeneic CAR-T immunotherapies using its TALEN® gene editing technology.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis, a clinical-stage biopharmaceutical company, is pioneering allogeneic CAR-T immunotherapies using its TALEN® gene editing technology. As of January 31, 2021, the company has a total of 43,029,305 shares and 49,093,894 voting rights. Cellectis focuses on developing UCART product candidates to treat unmet medical needs in various cancers including acute myeloid leukemia and multiple myeloma. The company operates in Paris, New York, and Raleigh, and is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).
Positive
- Development of innovative CAR-T therapies targeting unmet needs in oncology.
- Significant expertise in gene editing with over 21 years in the industry.
Negative
- None.
Details
News Market Reaction – CLLS
The recorded move for CLLS in the trading session of this news was +2.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 01/31/2021 | 43,029,305 | 49,093,894 |
About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
TALEN® is a registered trademark owned by Cellectis.
For further information, please contact:
Media contacts:
Jennifer Moore, SVP, Public Relations & NY Site Head 917-580-1088, media@cellectis.com
IR contact:
Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com
PDF available at: http://ml.globenewswire.com/Resource/Download/b0bfbf12-944e-41fa-846f-2df5a4b5900d
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.